vs

Side-by-side financial comparison of InvenTrust Properties Corp. (IVT) and MEDIFAST INC (MED). Click either name above to swap in a different company.

InvenTrust Properties Corp. is the larger business by last-quarter revenue ($77.4M vs $75.1M, roughly 1.0× MEDIFAST INC). On growth, InvenTrust Properties Corp. posted the faster year-over-year revenue change (8.6% vs -36.9%). InvenTrust Properties Corp. produced more free cash flow last quarter ($110.9M vs $-6.6M). Over the past eight quarters, InvenTrust Properties Corp.'s revenue compounded faster (7.6% CAGR vs -34.4%).

InvenTrust Properties Corp. is a real estate investment trust that invests in shopping malls. As of December 31, 2024, the company owned interests in 68 properties comprising 11.0 million square feet.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

IVT vs MED — Head-to-Head

Bigger by revenue
IVT
IVT
1.0× larger
IVT
$77.4M
$75.1M
MED
Growing faster (revenue YoY)
IVT
IVT
+45.5% gap
IVT
8.6%
-36.9%
MED
More free cash flow
IVT
IVT
$117.5M more FCF
IVT
$110.9M
$-6.6M
MED
Faster 2-yr revenue CAGR
IVT
IVT
Annualised
IVT
7.6%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IVT
IVT
MED
MED
Revenue
$77.4M
$75.1M
Net Profit
$2.7M
Gross Margin
69.4%
Operating Margin
-11.0%
-10.4%
Net Margin
3.4%
Revenue YoY
8.6%
-36.9%
Net Profit YoY
-72.8%
EPS (diluted)
$0.02
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVT
IVT
MED
MED
Q4 25
$77.4M
$75.1M
Q3 25
$74.5M
$89.4M
Q2 25
$73.6M
$105.6M
Q1 25
$73.8M
$115.7M
Q4 24
$71.2M
$119.0M
Q3 24
$68.5M
$140.2M
Q2 24
$67.4M
$168.6M
Q1 24
$66.8M
$174.7M
Net Profit
IVT
IVT
MED
MED
Q4 25
$2.7M
Q3 25
$6.0M
$-2.3M
Q2 25
$95.9M
$2.5M
Q1 25
$6.8M
$-772.0K
Q4 24
$9.8M
Q3 24
$-539.0K
$1.1M
Q2 24
$1.5M
$-8.2M
Q1 24
$2.9M
$8.3M
Gross Margin
IVT
IVT
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
IVT
IVT
MED
MED
Q4 25
-11.0%
-10.4%
Q3 25
-9.8%
-4.6%
Q2 25
-1.0%
Q1 25
-10.5%
-1.1%
Q4 24
-3.6%
0.6%
Q3 24
-18.7%
1.5%
Q2 24
-13.6%
-4.7%
Q1 24
-13.1%
4.5%
Net Margin
IVT
IVT
MED
MED
Q4 25
3.4%
Q3 25
8.1%
-2.5%
Q2 25
130.4%
2.3%
Q1 25
9.2%
-0.7%
Q4 24
13.8%
Q3 24
-0.8%
0.8%
Q2 24
2.2%
-4.8%
Q1 24
4.3%
4.8%
EPS (diluted)
IVT
IVT
MED
MED
Q4 25
$0.02
$-1.64
Q3 25
$0.08
$-0.21
Q2 25
$1.23
$0.22
Q1 25
$0.09
$-0.07
Q4 24
$0.14
$0.08
Q3 24
$-0.01
$0.10
Q2 24
$0.02
$-0.75
Q1 24
$0.04
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVT
IVT
MED
MED
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
$825.9M
Stockholders' EquityBook value
$1.8B
$198.9M
Total Assets
$2.8B
$248.0M
Debt / EquityLower = less leverage
0.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVT
IVT
MED
MED
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Q1 24
$156.4M
Total Debt
IVT
IVT
MED
MED
Q4 25
$825.9M
Q3 25
$764.6M
Q2 25
$746.3M
Q1 25
$740.7M
Q4 24
$740.4M
Q3 24
$740.1M
Q2 24
$812.2M
Q1 24
$827.5M
Stockholders' Equity
IVT
IVT
MED
MED
Q4 25
$1.8B
$198.9M
Q3 25
$1.8B
$214.7M
Q2 25
$1.8B
$216.0M
Q1 25
$1.7B
$211.0M
Q4 24
$1.8B
$210.1M
Q3 24
$1.8B
$207.3M
Q2 24
$1.5B
$205.3M
Q1 24
$1.5B
$211.0M
Total Assets
IVT
IVT
MED
MED
Q4 25
$2.8B
$248.0M
Q3 25
$2.7B
$268.2M
Q2 25
$2.7B
$269.3M
Q1 25
$2.6B
$280.0M
Q4 24
$2.6B
$284.2M
Q3 24
$2.6B
$291.2M
Q2 24
$2.5B
$293.5M
Q1 24
$2.5B
$302.8M
Debt / Equity
IVT
IVT
MED
MED
Q4 25
0.46×
Q3 25
0.42×
Q2 25
0.41×
Q1 25
0.42×
Q4 24
0.42×
Q3 24
0.42×
Q2 24
0.53×
Q1 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVT
IVT
MED
MED
Operating Cash FlowLast quarter
$155.4M
$-5.3M
Free Cash FlowOCF − Capex
$110.9M
$-6.6M
FCF MarginFCF / Revenue
143.3%
-8.8%
Capex IntensityCapex / Revenue
57.5%
1.8%
Cash ConversionOCF / Net Profit
58.41×
TTM Free Cash FlowTrailing 4 quarters
$193.1M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVT
IVT
MED
MED
Q4 25
$155.4M
$-5.3M
Q3 25
$43.8M
$12.1M
Q2 25
$48.7M
$-3.4M
Q1 25
$20.2M
$3.4M
Q4 24
$136.9M
$-4.9M
Q3 24
$38.4M
$9.1M
Q2 24
$46.7M
$13.1M
Q1 24
$14.8M
$7.3M
Free Cash Flow
IVT
IVT
MED
MED
Q4 25
$110.9M
$-6.6M
Q3 25
$31.4M
$10.8M
Q2 25
$38.0M
$-4.8M
Q1 25
$12.8M
$1.9M
Q4 24
$100.8M
$-7.2M
Q3 24
$29.3M
$7.7M
Q2 24
$37.2M
$11.1M
Q1 24
$7.7M
$5.4M
FCF Margin
IVT
IVT
MED
MED
Q4 25
143.3%
-8.8%
Q3 25
42.2%
12.0%
Q2 25
51.6%
-4.5%
Q1 25
17.4%
1.6%
Q4 24
141.5%
-6.1%
Q3 24
42.8%
5.5%
Q2 24
55.2%
6.6%
Q1 24
11.5%
3.1%
Capex Intensity
IVT
IVT
MED
MED
Q4 25
57.5%
1.8%
Q3 25
16.7%
1.5%
Q2 25
14.6%
1.3%
Q1 25
10.0%
1.3%
Q4 24
50.7%
1.9%
Q3 24
13.3%
1.0%
Q2 24
14.0%
1.1%
Q1 24
10.6%
1.1%
Cash Conversion
IVT
IVT
MED
MED
Q4 25
58.41×
Q3 25
7.27×
Q2 25
0.51×
-1.36×
Q1 25
2.97×
Q4 24
13.97×
Q3 24
8.04×
Q2 24
31.15×
Q1 24
5.10×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons